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Abstract
Smoking is a major cause of cardiovascular diseases, respiratory diseases and cancer. Despite the high prevalence of 
smokers worldwide, smokers are often neglected and not offered effective assistance with quitting their habits. In order to 
overcome this public health burden, effective treatment is needed to help smokers stop smoking. Among the pharmacological 
treatments available, nicotine-replacement therapy (NRT), when prescribed in combination with behavioural support, has 
been proven to be effective in helping a wide range of smokers to quit.  NRT helps smokers during the withdrawal process 
by replacing a proportion of the nicotine formerly obtained from cigarettes. NRT is available in many formulations. The 
commonly prescribed formulations are nicotine gum, nicotine patches, nicotine inhaler and nicotine nasal spray. The 
choice of which NRT to prescribe depends on the patient’s condition, established guidelines and protocols and availability. 
This article aims to review the role of NRT in smoking cessation.   
 Peer reviewed. (Submitted: 2009-08-31, Accepted: 2009-01-10). © SAAFP SA Fam Pract 2010;52(4):298-303
Introduction
Cigarette smoking, a leading cause of morbidity and 
mortality, is associated with cardiovascular and respiratory 
diseases, cancer and stroke. The World Health Organization 
(WHO) reported that cigarette smoking presently kills up to 
four million people annually and that, by the year 2030, up 
to 10 million smokers will die annually worldwide.1 Cigarette 
smoking is also a major public health concern in South 
Africa. The prevalence of smoking is 27.1% among men 
and 8.9% among women. The Medical Research Council 
reported that 8% of deaths in South Africa are attributed 
to cigarette smoking.2 Therefore, it is important to establish 
effective treatments to help current smokers to stop 
smoking.
Nicotine has been recognised as the main substance 
responsible for tobacco dependence. The inability of or 
difficulty for many smokers to stop smoking is mainly 
due to the addictive properties of nicotine.3 Nicotine in 
cigarettes acts as a pharmacological agent that reinforces 
the consumption of cigarettes and produces significant 
withdrawal symptoms in its absence.4 In recent years, the 
literature has reported newer drugs for smoking-cessation 
treatment.5 Several pharmacotherapies are available 
to assist smoking intervention strategies. One of the 
established pharmacotherapies for smoking cessation is 
nicotine-replacement therapy (NRT). Many clinical guidelines 
recommend NRT as a first-line treatment for smokers 
seeking pharmacological treatment to stop smoking.5,6 NRT 
helps smokers to alleviate withdrawal symptoms associated 
with smoking cessation by replacing a proportion of the 
nicotine formerly obtained from cigarettes.5,7 This article 
aims to briefly review NRT as a pharmacological aid for 
smoking-cessation treatment.
Source of data
A search of the literature was conducted using the Cochrane 
Library and OvidMedline up to 8 January 2010 using the 
keywords “nicotine”, “replacement”, “primary care”, “family” 
and “medicine”. The search produced a total of 104 articles 
on nicotine replacement and primary care and 20 articles on 
NRT and family medicine from Ovid Medline and four articles 
from Cochrane Library. Articles chosen were narrowed down 
to those published in English and limited to studies done 
on human subjects. Case reports, meta-analyses, review 
articles and clinical trials evaluating the safety, efficacy and 
adverse effects of NRT were included.5,8–10 
Nicotine-replacement therapy 
NRT aims to replace the nicotine obtained from cigarettes, 
thereby reducing withdrawal symptoms when stopping 
smoking. Worldwide, NRT is available in a variety of 
formulations, such as chewing gum, transdermal patches, a 
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nasal spray, an inhaler, sublingual tablets and lozenges.5,10,11 
The Cochrane Review (2008) of over 132 trials of NRT 
involving more than 40 000 people found that NRT helped 
smokers to stop smoking by increasing the chances 
of cessation by 50 to 70%, with or without additional 
counselling.5 NRT was shown to be effective for smoking 
cessation with or without additional counselling, although 
heavy smokers may require higher doses of NRT than 
smokers who smoke fewer cigarettes.5,10,12–14 
The dose of nicotine replacement required by the individual 
smoker depends on the usual nicotine consumption 
(amount of tobacco or number of cigarettes), and the ‘form’ 
and strength of nicotine content.5,10 It is recommended 
that the initial dose be sufficiently high to allow complete 
suppression of nicotine withdrawal symptoms and gradually 
reduced as tobacco abstinence is established.10,11
In South Africa, a special formulation of NRT is available 
as a nicotine mouth spray.15 Among the NRT formulations 
available, nicotine patches are considered a ‘passive’ 
dosing form, as they are applied once a day and nicotine 
is slowly absorbed though the skin.5,16 Nicotine gum, 
lozenges, sublingual tablets and inhalers are ‘acute’ dosing 
forms, as they allow the smoker to self-administer a dose 
of nicotine on an as-needed basis.5,17,18 Acute-dosing 
products are more beneficial for some smokers as they can 
titrate the amount and timing of doses. Thus, smokers with 
greater withdrawal symptoms can titrate a higher dose of 
nicotine, and those with acute adverse effects can reduce 
their nicotine intake.5,10,19 
NRT relieves withdrawal symptoms by substituting some of 
the nicotine normally obtained from cigarettes.4 The degree 
of relief obtained is related to the dose. Studies have reported 
that many smokers did not take optimum doses of NRT for 
a variety of reasons. Some stopped using it due to adverse 
effects, some were afraid of becoming dependent on NRT, 
some falsely believed that nicotine caused tobacco-related 
disease and others denied being addicted to nicotine and 
failed to understand medical treatment.10,18,20 
In smoking-cessation therapy, an adequate dosage of NRT 
is important to control craving and withdrawal symptoms in 
order to prevent relapse.18 It is reported that combination 
NRT treatment was superior to single NRT treatment in 
achieving one-year abstinence rates,5,21 and that treatment 
duration had to be long enough to control symptoms that 
persisted several weeks after cessation.22
Recently, it has been suggested that if a smoker was not able 
to stop smoking completely, sustained smoking reduction 
would be beneficial as it reduces exposure to tobacco 
smoke. It was also suggested that smoking reduction might 
motivate smokers to stop by gradually allowing them to 
take control of their smoking.23 NRT has been reported to 
help sustain and achieve smoking reduction, where 10% 
of subjects on NRT who had earlier stated that they were 
unwilling or unable to stop smoking at baseline were 
abstinent at two years.24 Furthermore, beside treatment for 
smoking cessation, the new indication for NRT was also 
for temporary abstinence (use of NRT to control nicotine 
craving and withdrawal symptoms during situations in 
which smokers were unable to smoke, as in the workplace, 
in hospitals or on long-haul flights). This could help smokers 
to familiarise themselves with NRT products, and may help 
them to stop smoking when they are ready to.11
Withdrawal symptoms 
Stopping smoking is difficult, as smokers experience 
withdrawal symptoms that begin within hours of smoking 
the last cigarette. The maximal intensity is felt within the first 
week and most of the affective symptoms reduce by four 
weeks.25 However, symptoms such as hunger and cravings 
may persist longer but these symptoms lessen over time.26 
Studies have observed heterogeneity in nicotine withdrawal 
symptoms among smokers trying to stop smoking.4,21 This 
variability in the pattern, severity and timing of withdrawal 
symptoms is important, as it could predict relapse 
after treatment.27 This observed variability means that 
therapy to treat nicotine withdrawal symptoms should be 
individualised. It was found that combined NRTs provide 
better relief of withdrawal symptoms. For example, the 
combination of a nicotine patch and another acute dosing 
formulation provides steady nicotine (through the patches) 
and immediate self-titrated relief (through the acute NRT 
such as a nicotine nasal spray, nicotine lozenge or nicotine 
gum) of the withdrawal symptoms.10,28
Cessation rates and efficacy
Earlier meta-analyses of 81 studies (49 on nicotine gum) 
that compared smoking-cessation rates with NRT or 
placebo reported that 18% of subjects receiving nicotine 
chewing gum were abstinent at 12 months, compared 
to 11% in the placebo group. The odds ratio for being 
abstinent with nicotine gum was 1.63 compared to placebo. 
The 4 mg of nicotine gum was better suited for the highly 
dependent smoker than the 2 mg.10,11,29 Recent evidence of 
the effectiveness of NRT for smoking cessation from the 
Cochrane Review (2008) of 111 trials of the five types of 
NRT formulations and over 43 000 subjects found that the 
risk ratio (RR) for nicotine gum was 1.43, 1.66 for nicotine 
patches, 1.90 for the nicotine inhaler, 2.00 for oral tablets/
lozenges and 2.02  for the nicotine nasal spray.5 A more 
recent study further confirmed that NRT was effective in 
maintaining smoking abstinence at six months, where 
smokers receiving NRT had double success rates of 
abstinence compared to placebo.10 Thus, NRT has been 
shown to be effective for smoking cessation at six months 
and at one year.
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Potential adverse effects of NRTs
Among the side effects reported were slight throat irritation, 
sore mouth, increased salivation and hiccups due to 
excessive swallowing of dissolved nicotine. Other adverse 
effects were gastrointestinal disturbances, including 
flatulence and borborygmi, headache, dizziness, nausea 
and vomiting. Less frequent adverse reactions include 
palpitations, erythema and urticaria. As for the potential 
for being addictive, it was reported that only about 5 
to 20% of smokers may become addicted to nicotine 
gum.11 NRT should be cautiously prescribed to patients 
with cardiovascular diseases. However, when compared 
to cigarettes, it was shown that NRT caused fewer 
cardiovascular effects than nicotine delivered by tobacco 
smoke, and that it is generally safe for the vast majority of 
smokers.30
Health risk of nicotine
One of the common reported misconceptions regarding 
NRT is the effect of nicotine on health.29 Nicotine addiction 
sustains smoking; however, it is the other components in 
cigarette smoke that cause lung cancer, chronic bronchitis 
and emphysema.31 It has been described that smokers 
smoke for nicotine, but die from tar, carbon monoxide and 
other harmful gases taken with the nicotine.32 Cigarette 
smoking causes acute cardiac events by producing a 
hypercoagualability state that promotes thrombosis. This is 
attributed to the bolus doses of nicotine in cigarette smoke 
and does not occur with the gradual delivery of nicotine via 
NRT.29 There is no evidence that NRT increases the risk of 
heart attacks.5
Dependence and abuse potential of NRT
The abuse potential of nicotine had been closely linked to 
the route of administration and resulting pharmacokinetic 
profile.29 The likelihood that a substance would be abused 
depends on the time between administration and central 
reinforcement.33 The addictiveness depends on the dose 
and speedy delivery to the brain. Cigarette smoking is 
addictive because nicotine is absorbed via the pulmonary 
circulation (rather than the systemic venous circulation), 
which means that nicotine reaches the brain in about 
10 seconds (more rapidly than via the intravenous route). 
Cigarettes also contain ammonia, which increases the 
pH of smoke and speeds up the delivery of free nicotine 
and theobromide, which dilates the airways and facilitates 
inhalation.29 In contrast, NRT has low potential of abuse 
as it does not produce the rapid, high arterial nicotine 
concentration that cigarettes do.33,34 
Nicotine gum
Nicotine gum has a tobacco-like, peppery taste. It is available 
in original, mint or citrus flavours. It is also available in 2-mg 
and 4-mg doses.5 The 2-mg gum is recommended to be 
prescribed to occasional smokers and those who smoke 
< 20 cigarettes per day. The 4-mg gum is recommended 
for smokers who smoke ≥ 20 cigarettes per day, for highly 
dependent smokers and for those who have withdrawal 
symptoms when taking the 2-mg gum.5,11,12
Smokers who are prescribed nicotine gum should be 
advised that chewing nicotine gum is not the same as 
chewing regular chewing gum. Nicotine gum should be 
chewed slowly until a slight tingling is felt in the mouth. 
The smoker should then stop chewing and place (park) 
the chewing gum between the cheek and gum. When 
the tingling sensation is diminished (after approximately 
one minute), the smoker is then advised to start chewing 
again. It is also important to inform the smoker not to chew 
nicotine gum too fast, not to chew more than one piece of 
nicotine gum at a time, and not to chew one piece too soon 
after another. Nicotine gum should be chewed for around 
30 minutes, and the administration could be repeated one 
to two hourly to prevent nicotine withdrawal symptoms, 
up to a maximum dose of 60 mg daily. After 20 minutes of 
intermittent chewing, almost 90% of the available nicotine 
is released from the gum. The availability is also dependent 
on the rate and intensity of chewing, the amount of saliva 
produced during chewing and whether saliva is swallowed 
or expectorated. The nicotine level rises faster than with a 
nicotine patch.11,12 Each piece of nicotine gum contains 2 mg 
or 4 mg of nicotine bound to an ion-exchange resin, which 
permits the slow release of nicotine. When administered, up 
to 50% of the nicotine content of the nicotine chewing gum 
is absorbed through the buccal mucosa. This absorption 
provides relief of nicotine withdrawal symptoms. Nicotine 
ingested through the gastrointestinal tract is extensively 
metabolised on first pass through the liver. Plasma nicotine 
concentration rises considerably slower than after smoking, 
with peak concentration occurring 30 minutes after initiation 
of chewing.35 Because of this slower rise, peak to trough 
nicotine concentrations vary less in a subject chewing 
one piece of gum compared to smoking one cigarette.36 It 
has been reported that after chewing a piece of nicotine 
gum, 0.8 mg nicotine is absorbed by buccal and 0.06 
mg nicotine is absorbed in the gut 37 The venous nicotine 
levels from the 2-mg and 4-mg gum were reported to be 
about one-third and two-thirds, respectively, of the steady-
state (i.e. between-cigarettes) levels of nicotine achieved 
with cigarette smoking (peak of 35 ng/ml and trough of 
25 ng/ml).35 Nicotine via cigarettes is absorbed directly into 
the arterial circulation; thus, arterial levels from smoking 
are reported to be five to ten times higher (peak nicotine 
concentration of 100 ng/ml) than those from the 2-mg and 
4-mg gums. 
The nicotine in the chewing gum is released at variable rates 
depending on the intensity and duration of chewing. In those 
who chew slowly and intermittently every few minutes, 
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nicotine is released continuously over 30 minutes.38 40 Thus, 
special instructions need to be given to patients on how to 
chew the nicotine gum, as chewing the gum rapidly may 
lead to excessive nicotine release, resulting in effect in 
‘over-smoking’, with side effects such as light-headedness, 
nausea, vomiting, hiccups, indigestion and throat irritation. 
The gum or the nicotine-rich saliva should not be swallowed 
as this may cause abdominal discomfort, heartburn and 
nausea.33,39 Other side effects of nicotine gum are difficulty 
in chewing, sore jaw, burning in the mouth and throat 
irritation.12,13
Nicotine gum reduced the incidence and severity of tobacco 
withdrawal symptoms, such as irritability, anger and 
impatience, more effectively than placebo when a nicotine-
dependent person was prohibited from smoking.41 It was 
also shown to markedly reduce the incidence and severity 
of hunger, which may persist for several weeks or months 
after stopping smoking.40,41 However, the results with regard 
to cravings were inconsistent. In an earlier study, Cohen et 
al41 showed that subjects had reduced craving symptoms 
when they chewed nicotine gum during temporary nicotine 
deprivation. However, later on, Cohen et al40 reported that 
the subjects did not report any reduction in craving. 
Studies by Silagy et al reported cessation rates after one 
year of treatment of 11% with placebo, 18% with 2-mg 
nicotine gum and 17% with 4-mg nicotine gum in those 
with mild nicotine dependence, and 8% with placebo, 
20% with 2-mg nicotine gum and 26% with 4-mg nicotine 
gum in those with severe nicotine dependence.11,12 When 
compared to placebo, the odds ratio for smoking cessation 
with nicotine gum was 1.63 (95% CI, 1.49–1.79).42
Nicotine patch
This transdermal formulation takes advantage of the ready 
absorption of nicotine across the skin. Patches are available 
as 24-hour and 16-hour patches. The patches are applied 
daily each morning, beginning upon cessation of smoking. 
Nicotine via patches is slowly absorbed. At the onset 
of use, venous nicotine levels peak six to ten hours after 
administration. Nicotine levels remain fairly steady with a 
decline from peak to trough of 25 to 40% with the 24-hour 
patches. Nicotine levels obtained with the use of patches are 
typically half of those obtained by smoking. The maximum 
plasma concentration of nicotine after application of a 
15 mg patch is between 9 and 15 ng/ml.14,43 The 
recommended dosage prescription for the nicotine 
patch is 21 mg/day for up to six weeks. After four to six 
weeks, patients are usually tapered to a middle dose (e.g. 
14 mg/24 hours or 10 mg/16 hours) and then again in two 
to four weeks to the lowest dose (7 mg/24 hours or 5 mg/ 
16 hours). However, smokers who smoked < 10 cigarettes/
day are recommended to start at a 14-mg/day dose instead 
of the 21-mg/day dose. The recommended total duration of 
treatment is usually six to twelve weeks. The common side 
effects of nicotine patches are skin reactions, insomnia, 
increased or vivid dreams and nausea.12,13
In a clinical trial comparing the 24-hour and 16-hour 
patches, it was found that the 21-mg/24-hour patch yielded 
consistently better control of cravings in the early morning 
and throughout the day, with greater reductions in anxiety, 
irritability and restlessness. Smokers using the 24-hour 
patches also had longer abstinence than those using the 
16-hour patches.44 The main advantage of nicotine patches 
over other nicotine formulations is that they are simple to 
use, and hence produce better compliance than the other 
nicotine formulations. On the other hand, nicotine patches 
do not adequately protect against acute cravings that may 
be provoked by smoking-related stimuli, as nicotine is 
delivered slowly.19
Nicotine nasal spray
Nicotine nasal spray is a nicotine solution in a nasal spray 
bottle. Each 10 ml of nasal spray bottle contains 100 mg 
of nicotine (10 mg/ml). Each nasal spray dose (two sprays, 
one in each nostril) averages about 1 mg of nicotine per 
administration. This formulation produces a more rapid rise 
in nicotine levels than nicotine gum; the rise in nicotine levels 
produced by nicotine spray falls between those produced 
by nicotine gum and cigarettes. Peak nicotine levels occur 
within 10 minutes, and venous nicotine levels are about 
two-thirds those of between-cigarettes levels. Reported 
venous concentrations of nicotine after a single 1-mg dose 
of nasal spray ranged between 5 and 12 ng/ml, and time to 
peak plasma concentration (T max) with nasal spray was 
11 to 13 minutes for a 1-mg dose. This time rise is slower 
than for delivery by cigarettes, but faster than other nicotine 
treatment products.45 Hurt et al suggested that a dose of 
1-mg nicotine nasal spray relieved spontaneous nicotine 
withdrawal symptoms, including cravings, more rapidly 
than a single dose of 4-mg nicotine gum.46 Smokers are 
advised to use the product for up to six months, including 
a tapering period. The common side effects reported are 
nasal and throat irritation, rhinitis, sneezing, coughing and 
watering eyes.12,13
Nicotine mouth spray
Nicotine mouth spray is a formulation of NRT specially 
available in South Africa. It is available in a treatment 
package of three strengths (initial at 1 mg per actuation 
of the vial and the last at 0.33 mg per actuation). This 
formulation has been tested in a randomised controlled 
trial in healthy smokers who wanted to stop smoking and 
its efficacy was found to be comparable to nicotine gum 
and nicotine inhaler.15 Smokers were also reported to prefer 
nicotine mouth spray over other formulations (nicotine gum, 
nicotine sublingual tablets and a nicotine nasal spray).47 The 
reported adverse effects were burning of the tongue/throat, 
nausea and hiccups.15 
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Nicotine inhaler
The nicotine inhaler is formed of plugs of nicotine placed 
inside hollow cigarette-like rods. The plugs produce a 
nicotine vapour when warm air is passed through them.48 
The product is not a true inhaler, as absorption is primarily 
by oral mucosa rather than through the bronchi or lungs.49 
Nicotine delivered via this method is 36% absorbed into the 
oral cavity, 36% in the oesophagus and stomach, and only 
4% by the lung.50 A dose consists of a puff or inhalation. 
Each cartridge contains 10 mg of nicotine, of which 4 mg of 
nicotine can be delivered, and 2 mg is absorbed. However, 
nicotine delivered primarily depends on the number of 
inhalations, where 80 puffs deliver 4 mg of nicotine. The 
recommended dosage is six to sixteen cartridges/day.51 
Nicotine inhalers produce venous nicotine levels that rise 
faster than with nicotine gum but slower than with the 
nicotine nasal spray, with nicotine blood levels of about 
one-third those of between-cigarettes levels.52 The inhaler 
was designed to satisfy the hand-to-mouth behavioural 
aspects of smoking and is recommended to be used for 12 
weeks, with a maximum of six months. The reported side 
effects are throat irritation and coughing.14,43
NRT in non-Caucasian populations
Most of the studies on NRT have been done and reported 
among the Caucasian population.17,53 Given the cultural and 
ethnic diversity of smokers in the world and in South Africa, 
there is a need to identify special characteristics of non-
Caucasian smokers and what works in these populations. 
Recent data support the use and efficacy of NRT in 
non-Caucasian populations.54 It was found that African-
American smokers displayed a preference for mentholated 
cigarettes and have higher salivary cotinine levels despite 
smoking fewer cigarettes. Similarly, South African black 
people smoke fewer cigarettes per day (< 10 cig/day) and 
many smoked mentholated brands. Smokers who smoked 
mentholated cigarettes were shown to be less successful at 
stopping smoking than those who smoked non-mentholated 
cigarettes. It has been suggested that black people who are 
light smokers and who smoke mentholated cigarettes may 
require higher doses of NRT to maintain abstinence.54–56
Comparison of NRT and other non-
nicotine medication for smoking 
cessation
A recent report found that NRT had similar efficacy 
to bupropion (NRT vs bupropion, OR, 1.09, 95% CI, 
0.93–1.31, p = 0.28) but however less efficacious than 
varenicline (varenicline vs NRT, OR 1.56, 95% CI, 1.23–1.96, 
p = 0.0002) in maintaining short-term smoking abstinence 
at four weeks.57 
Conclusion
Cigarette smoking is associated with significant morbidity 
and mortality. Therefore, aggressive efforts are needed to 
promote smoking cessation and to treat smokers. Effective 
treatments combined with behavioural support and the 
5 As framework of smoking cessation of Ask, Advise, 
Assess, Assist and Arrange should be offered to every 
smoker who is motivated to stop smoking. NRT has been 
available for more than two decades and has been shown 
to be safe and effective for stopping smoking. 
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